It’s in the blood: Patient-derived hematologic malignancy models in research

Logo
Presented by

Amy Wesa, PhD, Director of Immuno-Oncology Research, Champions Oncology

About this talk

Hematological malignancies are cancers that begin in the cells of blood-forming tissue or in the cells of the immune system. These types of cancer, specifically, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Multiple Myeloma (MM) are on the rise in the aging population globally. In this webinar, Dr. Wesa will demonstrate how patient-derived hematologic malignancy in vivo and ex vivo models can be used to advance drug development. Viewing this webinar will help you to: •Develop an understanding of a robust approach to human AML Patient-derived Xenograft (PDX) in vivo models •Learn how to select study endpoints for in vivo and ex vivo models •Learn how to advance early stage compounds through Champions’ hematologic Vitroscreen for AML, B-ALL and MCL Disease indications

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (50)
Subscribers (2623)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.